HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: P&G

This article was originally published in The Rose Sheet

Executive Summary

P&G: Inspecting inventories of Oil Of Olay Revitalizing Eye Gel following reports of defective jars at one of its manufacturing plants. While inspecting 25,000 jars in its inventory, Procter & Gamble found eight jars with a half-inch glass spike, visible from the outside, originating from the bottom of the jar, the company said. Sixty thousand products from the suspect lot have already been shipped to retailers. The company predicts that one out of every 3,000 jars, or a total of 20 products, may be defective, with "fewer than 10" spike-containing jars estimated to already be in consumers' hands. The firm maintained that "there's no risk of serious health or safety problems," but is encouraging consumers to "check their packages at home" and call the company's toll-free number with any questions...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002512

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel